Skip to content
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Loading stock detail

Preparing the latest stock view…

We're pulling the screening verdict, quote snapshot, and company context now.

Is Jubilant Pharmova Ltd. Shariah Compliant? | BarakFi | BarakFi
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80−0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90−0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42−2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Home›Screener›JUBLPHARMA
JUBLPHARMA logo
JUBLPHARMANSE

Jubilant Pharmova Ltd.

Healthcare · Mid Cap · India
₹970.8
▼ ₹20.95 (-2.11%) today
Day Range: ₹964.2 – ₹975.55
Volume: 19.2K · as of 3 Jun 2026, 1:37 pm
Shariah Status
Shariah Compliant
Report Credit
Opening this stock page uses 1 of your 50 monthly report credits.
Last screened 2 Jun 2026, 7:35 pm IST.
Methodology
AAOIFI aligned · 2026.04.2
See Full Breakdown
Shariah Compliant
Compliance
Market Data
About
Similar Stocks
Add to Watchlist
Share
Shariah Compliance Breakdown
Debt Ratio
Interest-bearing debt compared to methodology denominator (AAOIFI: total assets). Must stay below 30%.
Disclaimer:The information on this page is for educational purposes only and does not constitute a religious ruling (fatwa) or financial advice. Shariah compliance status is derived from publicly available financial data and BarakFi's methodology mapping. Individual scholars may reach different conclusions. Always consult a qualified Islamic finance scholar and a licensed financial advisor before making investment decisions.
BarakFi

Shariah-compliant equity screening for the Indian market.

support@barakfi.inBarakFi on LinkedIn
Product
ScreenerWatchlistTrending
Resources
Halal Stocks IndiaAbout UsMethodologyPurification
Legal
TermsPrivacyDisclaimer
© 2026 BarakFi · Educational screening · Not a religious ruling or financial adviceMade in India
Threshold: 30%
20.7%
Pass
Interest Income
Interest and treasury-based income as a share of business income. Must stay below 5%.
Threshold: 5%
0.0%
Pass
Non-permissible Income
Non-halal income compared to total business income. Must stay below 5%.
Threshold: 5%
Not detected
Pass
Accounts Receivable
Receivables compared to methodology denominator (AAOIFI: total assets). Must stay below 49%.
Threshold: 49%
6.9%
Pass
Business Activity
Core business lines should avoid prohibited sectors and interest-driven revenue dependence.
Allowed
Pass
Cash & Interest-bearing Assets
Cash, equivalents, and interest-bearing balances compared to total assets. Must stay below 30%.
Threshold: 30%
8.2%
Pass
Why Shariah Compliant
Jubilant Pharmova Ltd. currently screens as Shariah compliant on BarakFi. All required checks pass with current data.
Market Data
Current Price
₹970.8
Day Range
₹964.2 – ₹975.55
52-Week Range
₹786.05 – ₹1,248
Volume
19.2K
Market Cap
₹15,444 Cr
P/E Ratio
—
About Jubilant Pharmova Ltd.

Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh and currently employs 1,034 full-time employees. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.

Index and universe context: Nifty 500 • Nifty SMALLCAP 100.

HealthcareMid CapIndiaNSENifty 500Nifty SMALLCAP 100
Other Stocks in Healthcare
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Compliant
MAXHEALTH
Max Healthcare Institute Limited
Compliant
ZYDUSLIFE
Zydus Lifesciences Limited
Compliant
MANKIND
Mankind Pharma Limited
Compliant
FORTIS
Fortis Healthcare Limited
Compliant
Key Compliance Ratios
Debt Ratio20.7%
Interest Income0.0%
Non-permissible IncomeNot detected
Receivables Ratio6.9%
Overall StatusCompliant
Stock Information
TickerJUBLPHARMA
ExchangeNSE
SectorHealthcare
CountryIndia
Market Cap₹15,444 Cr
36M Avg MCap₹15,771 Cr
Cap SizeMid Cap
About this Screening
This page uses an AAOIFI-aligned methodology version 2026.04.2, checking debt, interest income, non-permissible income, receivables, and balance-sheet context from the current filings dataset.

This is educational only — not a religious ruling or financial advice. Read the full methodology for threshold context and update cadence.

Read full methodology →
Track this stock
Add JUBLPHARMA to your watchlist so you can revisit its status after the next fundamentals sync.
Open Watchlist